Inhibition of CXCR1 and CXCR2 blocks allergen challenge-induced
allergic lung inflammation
Ladaraxin is an orally bio-available allosteric inhibitor of CXCR1 and
CXCR2. Ladarixin treatment of naïve mice subjected to CDE-SCM
(Fig 1B ) reduced CDE challenge-induced innate neutrophil
recruitment into the lung by 30% (Fig 1C ). Next, we compared
to PBS challenge, CDE challenge in CDE-MCM (Fig 1A ) increased
the number of total cells, macrophages, neutrophils, and eosinophils in
BALF (Fig 1D ) and lung tissues quantified by flow cytometry at
72 h after the final CDE challenge (Fig 1E ), as well as total
IgE and CDE-specific IgE in serum (Fig 1F ). Oral administration
of ladarixin in CDE-MCM model (Fig 1A , right panel) inhibited
each of these parameters (Fig 1D-F ).